Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: SnowShredder who wrote (14024)	2/1/1998 4:42:00 PM
From: Cacaito	Respond to of 32384

Off topic: about Aronex's Zintevir: ncbi.nlm.nih.gov I think (not sure) zintevir will avoid entrance to the potential host cell, and avoid integration to the host DNA (second effect more important). About any ability of the virus to change its behavior and reproduce in a different way, similar to an adenovirus? I do not know, but hopefully not (or this virus is really invincible). The Aronex side have a nice graphic about the process. In the article above they even talk about resistant strains to Zintevir. I guess it will be at some point another drug for the different cocktails available to HIV patients.